Regeneron 2023 10-K Filed: Financials Revealed

TL;DR

**Regeneron's 2023 financials are out, giving a clear picture of their revenue streams.**

AI Summary

Regeneron Pharmaceuticals, Inc. filed its 10-K for the fiscal year ending December 31, 2023, on February 5, 2024. The filing provides a comprehensive overview of the company's financial performance, including product revenue, collaboration revenue, and other service revenue for 2023, 2022, and 2021. This matters to investors as it offers transparency into the company's financial health and operational results, which are crucial for evaluating its past performance and future potential.

Why It Matters

This filing provides a detailed look at Regeneron's financial performance, allowing investors to assess its profitability and growth trajectory, which directly impacts stock valuation.

Risk Assessment

Risk Level: medium — The pharmaceutical industry faces inherent risks from R&D failures, regulatory hurdles, and market competition, making it a medium-risk investment.

Analyst Insight

Investors should review the detailed financial statements within the 10-K to understand the specific revenue figures for product sales and collaboration agreements for 2023, 2022, and 2021 to gauge growth trends.

Key Numbers

• 2023-12-31 — Fiscal Year End (The period covered by the financial statements in the 10-K.)
• 0000872589 — Central Index Key (CIK) (Unique identifier for Regeneron Pharmaceuticals, Inc. with the SEC.)
• 139 — Public Document Count (The number of documents included in this specific 10-K filing.)
• 19930328 — Date of Name Change (The date Regeneron Pharmaceuticals Inc. changed its name to REGENERON PHARMACEUTICALS, INC.)
• 10591 — Zip Code (The business and mail address zip code for Regeneron Pharmaceuticals, Inc.)

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — the filer of the 10-K
• Robert E. Landry (person) — mentioned in the context of the filing period
• 2023 (date) — the fiscal year covered by the 10-K
• December 31, 2023 (date) — the end of the fiscal year
• February 5, 2024 (date) — the filing date of the 10-K

Forward-Looking Statements

• Regeneron will continue to report product revenue as a primary income stream. (REGENERON PHARMACEUTICALS, INC.) — high confidence, target: 2024-12-31

FAQ

From the Filing

0001804220-24-000009.txt : 20240205 0001804220-24-000009.hdr.sgml : 20240205 20240205091615 ACCESSION NUMBER: 0001804220-24-000009 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 139 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 24594245 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 10-K 1 regn-20231231.htm 10-K regn-20231231 0000872589 2023 FY false 179 http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent 0000872589 2023-01-01 2023-12-31 0000872589 2023-06-30 iso4217:USD 0000872589 us-gaap:CommonClassAMember 2024-01-25 xbrli:shares 0000872589 us-gaap:CommonStockMember 2024-01-25 0000872589 2023-10-01 2023-12-31 0000872589 regn:RobertELandryMember 2023-10-01 2023-12-31 0000872589 regn:RobertELandryMember 2023-12-31 0000872589 2023-12-31 0000872589 2022-12-31 iso4217:USD xbrli:shares 0000872589 us-gaap:CommonClassAMember 2023-12-31 0000872589 us-gaap:CommonClassAMember 2022-12-31 0000872589 us-gaap:CommonStockMember 2022-12-31 0000872589 us-gaap:CommonStockMember 2023-12-31 0000872589 us-gaap:ProductMember 2023-01-01 2023-12-31 0000872589 us-gaap:ProductMember 2022-01-01 2022-12-31 0000872589 us-gaap:ProductMember 2021-01-01 2021-12-31 0000872589 regn:CollaborationRevenueMember 2023-01-01 2023-12-31 0000872589 regn:CollaborationRevenueMember 2022-01-01 2022-12-31 0000872589 regn:CollaborationRevenueMember 2021-01-01 2021-12-31 0000872589 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-12-31 0000872589 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-12-31 0000872589 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0000872589 2022-01-01 2022-12-31 0000872589 2021-01-01 2021-12-31 0000872589 regn:CollaborationandContractManufacturingMember 2023-01-01 2023-12-31 0000872589 regn:CollaborationandContractManufacturingMember 2022-01-01 2022-12-31 0000872589 regn:CollaborationandContractManufacturingMember 2021-01-01 2021-12-31 0000872589 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-12-31 0000872589 us-gaap:CommonStockMember 2020-12-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000872589 us-gaap:RetainedEarningsMember 2020-12-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000872589 us-gaap:TreasuryStockCommonMember 2020-12-31 0000872589 2020-12-31 0000872589 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000872589 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0000872589 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000872589 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0000872589 us-gaap:CommonStockMember 2021-12-31 0000872589 us-gaap:AdditionalPaidInCa